Arcus Biosciences (RCUS) Misses Q1 EPS by 12c

Arcus Biosciences (NYSE: RCUS) reported Q1 EPS of ($1.14), $0.12 worse than the analyst estimate of ($1.02). Revenue for the quarter came in at $28 million versus the consensus estimate of $38.61 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Correction: Kepler Cheuvreux Upgrades Siemens AG (SIE:GR) (SIEGY) to Hold
• RBC Capital Upgrades GEA Group AG (G1A:GR) (GEAGY) to Outperform